Abstract 2350P
Background
Liver metastasis (LM) frequently occurs in patients with various cancers; yet our understanding of the underlying salient biology is preliminary. So far, no studies have found the initiating liver metastasis cells and specific liver metastatic microenvironment in various cancers. Here, we performed single-cell RNA-seq in eight patients with LM of various cancers to solve this scientific blind spot.
Methods
Single cell RNA sequencing was performed on tissues from LM of various cancers (gastric cancer(n=2); esophageal cancer(n=1); breast cancer(n=1); lung cancer(n=3); colorectal cancer(n=1)). Also, we downloaded the single-cell RNA-seq of hepatocellular carcinoma (HCC) and corresponding five types of cancer from GEO database. Seurat were applied to sort single-cell RNA-seq of LM in various cancers and corresponding five types of primary cancer into different clusters via feature dimension reduction. Furthermore, flow cytometry was used to sort those initiating liver metastasis cells, and then those cells was verified by cell metastasis function experiment and caudal vein injection of mice.
Results
The transcriptomes of 90035, 78933, 105340 single cells among LM in various cancers, HCC, and corresponding primary cancers were extracted respectively. There were 14 clusters divided into epithelial cells of liver metastasis single cells. Differential gene analyses and ratio analyses in LM and corresponding primary cancers groups showed that C10 and C12 might be the LM initiating cells clusters. And they were both enriched in the positive regulation of cell migration. SOX6+ CD52+ epithelial cells might be the LM initiating cells in various cancers, of which promoted cancer stem cells migration. Cohorts in TCGA database also showed a worse prognosis for patients with SOX6+ CD52+ markers. The sorting SOX6+ CD52+ epithelial cells will be further verified in metastasis function experiment and caudal vein injection of mice in vitro and in vivo.
Conclusions
The initiating liver metastasis cells in various cancers has been found and verified in this study, which provided a further understanding of the potential biological mechanisms of LM in various cancers and potential target for the novel drugs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Science and Natural Science Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2346P - Spatial and quantified molecular characterization of high endothelial venule predictive of immunotherapy response
Presenter: Kunheng Du
Session: Poster session 16
2347P - Correlation between second primary cancers and first primary cancers: A systematic review and meta-analysis of 9 million cancer patients
Presenter: Xinyu Wang
Session: Poster session 16
2348P - High-throughput screening reveals GSK1838705A as a potent inhibitor of CAFs-promoted tumor progression in esophageal squamous cell carcinoma
Presenter: hongfang zhang
Session: Poster session 16
2349P - Patterns and frequency of pathogenic germline variants (PGVs) among non-western young male patients with cancer: The Jordanian exploratory cancer genetics (Jo-ECAG) study
Presenter: Hira Bani Hani
Session: Poster session 16
2351P - Whole genome sequencing of AYA patients
Presenter: Paul Roepman
Session: Poster session 16
2352P - Sex-based differences in genomic alterations and biomarkers in anal squamous cell carcinoma (ASCC)
Presenter: Stefano Cereda
Session: Poster session 16
2353P - Anti-cancer effects of HDAC8 specific inhibitors EC-352H and EC-374H in lymphoma
Presenter: So Young Lee
Session: Poster session 16
2354P - Computational pathology-derived features capture varied epithelial-mesenchymal transition (EMT) states
Presenter: Herbert Levine
Session: Poster session 16
2355P - Carcinoembryonic antigen (CEA) expression in human tumors: A tissue microarray study on 15,413 tumors
Presenter: Kristina Jansen
Session: Poster session 16
2356P - The role of pathological features in predicting prognosis of patients with advanced RET-positive NSCLC
Presenter: Arianna Marinello
Session: Poster session 16